Pfizer shares fall on report company cut its Covid vaccine rollout target


A haulage truck and traffic pass the Pfizer Inc. facility in Puurs, Belgium, on Thursday, Dec. 3, 2020.

Geert Vanden Wijngaert | Bloomberg | Getty Images

Pfizer shares fell Thursday after a report said the U.S. drugmaker expects to ship half of the Covid-19 vaccines it originally planned for this year due to supply-chain problems.

The Wall Street Journal, citing a person directly involved in the development, said some early batches of the raw materials needed for the vaccine failed to meet standards. Pfizer now plans to ship 50 million vaccines by the end of the year, down from the original 100 million it had hoped to send out, according to the Journal.

“There are several factors which have impacted the number of doses estimated to be available in 2020,” Pfizer said in a statement. “For one, scaling up a vaccine at this pace is unprecedented, and we have made significant progress as we have moved forward in the unknown.”

The company has repeatedly said publicly that it planned to ship 50 million vaccine doses this year and up to 1.3 billion doses by the end of 2021. Still, Pfizer shares fell more than 2% in intraday trading Thursday before closing down more than 1% after the report published.

Pfizer said Thursday, the scale up of the raw material supply chain took longer than expected. It also was delayed by the efforts it was making to produce vaccines for clinical trials. The company said its full scale production lines in the U.S. and Europe are now complete and it is “confident” it will be able to supply the targeted doses.

Pfizer, which has been working alongside German drugmaker BioNTech, applied for an emergency use authorization from the Food and Drug Administration for their coronavirus vaccine on Nov. 20. Its vaccine uses messenger RNA, or mRNA, technology. It’s a new approach to vaccines that uses genetic material to provoke an immune response.

Pfizer announced on July 22 that the U.S. agreed to buy 100 million doses of its vaccine for up to $1.95 billion. The agreement, part of the Trump administration’s vaccine program Operation Warp Speed, allows the U.S. to acquire an additional 500 million vaccine doses

On Wednesday, The U.K. authorized Pfizer’s vaccine, becoming the first country to do so.

This is a developing story. Please check back for updates.

Articles You May Like

Here’s what it costs to book Disney’s new cruises to Antarctica and the Galapagos Islands
Citigroup beats analysts’ profit estimates as bank releases money set aside for loan losses
Cathie Wood’s ARK Invest plans ‘ARKX’ space exploration ETF to tap the growing industry
Biden pushes for bigger benefits for Americans struggling with hunger
Jamie Dimon says JPMorgan Chase should absolutely be ‘scared s—less’ about fintech threat

Leave a Reply